Core Insights - CalciMedica Inc. reported positive data from the Phase 2b CARPO trial of Auxora™ in acute pancreatitis, indicating a potential for initiating a Phase 3 program in 2025 [1][4][3] - The company is actively enrolling patients in the Phase 2 KOURAGE trial for acute kidney injury and the Phase 2 CRSPA trial for asparaginase-induced pancreatic toxicity, with data expected in 2025 [1][5][6] - Following a public offering, CalciMedica's cash position is projected to support operations into the first half of 2026 [1][7] Clinical Updates - The CARPO trial demonstrated a 100% relative risk reduction in new-onset severe respiratory failure (p = 0.0027) and a 64.2% reduction in new-onset persistent respiratory failure (p = 0.0476) for high and medium dose Auxora patients compared to low dose and placebo [3] - A statistically significant win ratio of 1.640 (p = 0.0372) was observed for high dose Auxora patients, along with clinically meaningful reductions in new-onset necrotizing pancreatitis and time to medically indicated discharge [3] Financial Results - As of September 30, 2024, CalciMedica had approximately $14.6 million in cash, cash equivalents, and short-term investments, which is expected to increase to about $23.7 million post-offering [7] - The company reported a total loss from operations of approximately $5.7 million for the three months ended September 30, 2024, and $18.0 million for the nine months ended September 30, 2024 [8][13] - The net loss for the same periods was approximately $5.6 million and $9.4 million, translating to a net loss per share of $0.50 and $0.88, respectively [8][13]
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates